Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Selection Haplo: HLA-haploidentical related donor selection with post-transplant cyclophosphamide for allo-HSCT in hematological malignancies
jRCTs051190011Recruiting
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute leukemia of ambiguous lineage (ALAL) and 5 more (2 arms). Primary endpoint: Progression-free survival by donor scoring group. Started Oct 2019; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs051190011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190011.